In the pancreas, GLP-1 receptor agonists enhance glucose-dependent insulin secretion whilst suppressing inappropriate glucagon release, thereby improving glycaemic control
Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic beta-cell impairments in type 2 diabetes
Access, Affordability, and Pricing Risks Perceived excessive and unjustified price increases, as well as regional cost disparities, have sparked public debate and criticism over companies pricing strategies for their GLP-1 medications
GLP-1 is produced primarily by specialized cells, called L-cells, in the lining of your small intestine
A 2026 market analysis reported that products positioned for blood sugar management accounted for 39.3% of the GLP-1 support supplement market, reflecting consumer interest in metabolic wellness and healthy glucose metabolism